

be used by CDC and local health department staff to assess changes made to the NHBS-Trans system to monitor the prevalence of HIV among transgender women of color and to strengthen understanding of the behavioral and environmental HIV risk factors that contribute to the disproportionately high prevalence of HIV within this population. Improved surveillance of transgender women is necessary to help CDC and health departments identify areas for community-level interventions, track the progress of communities in implementing change, and evaluate interventions that seek to reduce HIV risk factors and increase engagement in HIV prevention and care.

CDC requests a three-year approval for a revised information collection. Based on completion of data collection in 2019–2020 and evaluation of the previous efforts, project activities and methods have expanded to allow for remote variants of our in-person methods, such as interview by videoconference or phone. The number of Metropolitan Statistical Areas (MSAs) participating in NHBS-Trans will increase (from nine to up to 14) and the number of respondents recruited per project area will increase from 200 to 300 adult minority transgender women (4,200 interviews total). Selected content of the eligibility screener and behavioral assessment was revised.

Data will be collected through anonymous, in-person interviews conducted with persons systematically selected from up to 14 MSAs throughout the United States. A brief screening interview will be used to determine eligibility for participation in the behavioral assessment. All participants will be provided HIV testing and referral to services (as needed) following CDC protocol. Each participant will respond one time over the course of the three-year project. Participants will be recruited through respondent-driven sampling (RDS), a scientifically proven recruitment strategy for reaching hidden, hard-to-reach, or stigmatized populations. To assess non-response bias from RDS, peer recruiters will be debriefed about their recruitment efforts when they return to the field site. This information will be used to understand if certain racial (or ethnic) groups are not responding or if persons are not responding for a particular reason. Interview data will be recorded on secure portable computers, without internet connections. Data will be transferred to secure, encrypted data servers. Data will be stored at CDC and shared with local health departments in accordance with existing data use agreements and the Assurance of Confidentiality for HIV/AIDS Surveillance Data. Data will be disseminated in aggregate through academic and agency publications,

presentations, and reports. The information will be collected over a three-year period beginning no later than two months after OMB approval.

The NHBS-Trans behavioral assessment and optional HIV testing are anonymous (neither names nor Social Security numbers are collected). Data that will be collected through NHBS-Trans, while sensitive, are not personally identifying. These data will provide estimates of (1) behavior related to the risk of HIV and other sexually transmitted diseases, (2) prior testing for HIV, and (3) use of HIV prevention services. No other federal agency systematically collects this type of information from persons at risk for HIV infection. These data have substantial impact on prevention program development and monitoring at the local, state, and national levels.

The burden table below shows the estimated annualized burden hours for the participants' time. Annually, 1,540 participants will complete an eligibility screener (an average of five minutes to complete), 1,400 participants will complete the Behavioral Assessment (an average of 40 minutes to complete), and 1,400 will complete the Recruiter Debriefing Form (an average of two minutes to complete). The estimated total annualized burden is 1,108 hours. Participation of respondents is voluntary, and there are no costs to respondents other than their time.

#### ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hours)
Transgender Women, >18 years old .....	Eligibility Screener .....	1,540	1	5/60
Eligible and Consenting Respondents .....	NHBS-Trans Behavioral Assessment .....	1,400	1	40/60
Peer Recruiters .....	Recruiter Debriefing Form .....	1,400	1	2/60

Jeffrey M. Zirger,

Lead, Information Collection Review Office,  
Office of Scientific Integrity, Office of Science,  
Centers for Disease Control and Prevention.

[FR Doc. 2022-05756 Filed 3-17-22; 8:45 am]

BILLING CODE 4163-18-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

##### Centers for Disease Control and Prevention

##### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; (SEP)—CE22-006, “Research Grants To Evaluate the Effectiveness of Physical Therapy-Based Exercises and Movements Used To Reduce Older Adults Falls (U01)”; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; (SEP)—CE22-006, “Research Grants To Evaluate the

Effectiveness of Physical Therapy-Based Exercises and Movements Used To Reduce Older Adults Falls (U01)”, May 17–18, 2022, 8:30 a.m., EDT–5:30 p.m., EDT, Web Conference, in the original FRN. The meeting was published in the **Federal Register** on January 14, 2022, Volume 87, Number 10, page/s/ 2438.

The meeting is being amended to change the meeting date and should read as follows: CE22-006, “Research Grants To Evaluate the Effectiveness of Physical Therapy-Based Exercises and Movements Used To Reduce Older Adults Falls (U01)”, May 17, 2022, 8:30 a.m., EDT–5:30 p.m., EDT.

The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:**  
Aisha L. Wilkes, M.P.H., Scientific

Review Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop S106–9, Atlanta, Georgia 30341, Telephone (404) 639–6473, *AWilkes@cdc.gov*.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022–05748 Filed 3–17–22; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; (SEP)—GH20–002, Malaria Operations Research to Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; GH20–003, Conducting Public Health Research in Colombia; GH21–003, Advancing Public Health Research in Kenya; and GH22–001, Enhancing Capacity for Strategic and Applied Research Activities in Support of Control and Elimination of Malaria and Other Parasitic Diseases.

*Date:* April 13, 2022.

*Time:* 9:00 a.m.–2:00 p.m., EDT.

*Place:* Teleconference.

*Agenda:* To review and evaluate grant applications.

**FOR FURTHER INFORMATION CONTACT:**

Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Road NE, Mailstop H21–9, Atlanta, Georgia 30329–4027, Telephone: (404) 639–4796; Email: *HShoob@cdc.gov*.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022–05751 Filed 3–17–22; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; (SEP)—CE22–008, “Using Data Linkage To Improve Our Understanding of Suicide/Self-Inflicted Injury and/or Drowning”; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE22–008, “Using Data Linkage to Improve Our Understanding of Suicide/Self-Inflicted Injury and/or Drowning”, May 24–25, 2022, 8:30 a.m., EDT–5:30 p.m., EDT, Videoconference, in the original FRN. The meeting was published in the **Federal Register** on January 14, 2022, Volume 87, Number 10, page/s/2440–2441.

The meeting is being amended to change the meeting date and should read as follows:

CE22–008, “Using Data Linkage to Improve Our Understanding of Suicide/Self-Inflicted Injury and/or Drowning”, May 24, 2022, 1:00 p.m., EDT–5:00 p.m., EDT.

The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:**

Mikel Walters, Ph.D., Scientific Review

Officer, National Center for Injury Prevention and Control, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341, Telephone (404) 639–0913, *MWalters@cdc.gov*.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022–05749 Filed 3–17–22; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket No. CDC–2022–0037; NIOSH 278]

#### Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following virtual meeting of the Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH). This is a virtual meeting and open to the public, limited only by web conference lines (500 web conference lines are available). Time will be available for public comment.

**DATES:** The meeting will be held on April 20, 2022, from 10:00 a.m.–3:00 p.m., EDT.

Written comments must be submitted by April 13, 2022.

**ADDRESSES:** This is a virtual meeting. You may submit comments, identified by Docket No. CDC–2022–0037; NIOSH–278 by mail. CDC does not accept comments by email.

• *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments.

• *Mail:* Docket number CDC–2021–0037; NIOSH–278, c/o Sherri Diana, NIOSH Docket Office, National Institute